These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). Echeverría P; Negredo E; Carosi G; Gálvez J; Gómez JL; Ocampo A; Portilla J; Prieto A; López JC; Rubio R; Mariño A; Pedrol E; Viladés C; del Arco A; Moreno A; Bravo I; López-Blazquez R; Pérez-Alvarez N; Clotet B Antiviral Res; 2010 Feb; 85(2):403-8. PubMed ID: 19941906 [TBL] [Abstract][Full Text] [Related]
28. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036 [TBL] [Abstract][Full Text] [Related]
29. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible. Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416 [No Abstract] [Full Text] [Related]
30. Raltegravir as effective as efavirenz in 144-week data. AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035 [No Abstract] [Full Text] [Related]
31. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150 [TBL] [Abstract][Full Text] [Related]
32. Efavirenz treatment and false-positive results in benzodiazepine screening tests. Blank A; Hellstern V; Schuster D; Hartmann M; Matthée AK; Burhenne J; Haefeli WE; Mikus G Clin Infect Dis; 2009 Jun; 48(12):1787-9. PubMed ID: 19432553 [TBL] [Abstract][Full Text] [Related]
33. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. Read TR; Carey D; Mallon P; Mijch A; Goodall R; Hudson F; Wand H; Emery S AIDS; 2009 Oct; 23(16):2222-3. PubMed ID: 19773634 [TBL] [Abstract][Full Text] [Related]
34. Does pregnancy affect the pharmacokinetics of efavirenz? Hill A; Ford N; Boffito M; Pozniak A; Cressey TR AIDS; 2014 Jun; 28(10):1542-3. PubMed ID: 24896806 [No Abstract] [Full Text] [Related]
35. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]. van Leth F; Lange JM Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943 [TBL] [Abstract][Full Text] [Related]
36. Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. Nijhawan AE; Zachary KC; Kwara A; Venna N AIDS Read; 2008 Jul; 18(7):386-8, C3. PubMed ID: 18655316 [TBL] [Abstract][Full Text] [Related]
37. [Tolerance study of a triple first-line antiretroviral combination zidovudine, lamivudine and efavirenz in Dakar, Senegal]. Seydi M; Diop SA; Dieng AB; Tekpa G; Soumaré M; Diouf A; Niang Kh; Lakh A; Ndiaye I; Fall MB; Diop BM; Sow A; Sow PS Bull Soc Pathol Exot; 2009 May; 102(2):99-100. PubMed ID: 19583031 [TBL] [Abstract][Full Text] [Related]
38. Maraviroc reduces viral load in naive patients at 48 weeks. AIDS Patient Care STDS; 2007 Sep; 21(9):703-4. PubMed ID: 17941136 [No Abstract] [Full Text] [Related]
39. Neuropsychiatric complications of antiretroviral therapy. Cespedes MS; Aberg JA Drug Saf; 2006; 29(10):865-74. PubMed ID: 16970510 [TBL] [Abstract][Full Text] [Related]
40. Transition modeling of neuropsychiatric impairment in HIV. Bisaso KR; Mukonzo JK; Ette EI Comput Biol Med; 2016 Jun; 73():141-6. PubMed ID: 27107677 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]